Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Diagnostics
Diagnostics · The big question

Routine PSA Tests Likely Save Lives, Updated Study Finds

Prostate-specific antigen (PSA) test for prostate cancer screening.

PubMed2 min readAI-assisted summary
Editorial illustration for Prostate-specific antigen (PSA) test for prostate cancer screening.
Editorial illustration

Summary

Prostate cancer screening has long been a subject of debate among medical professionals. Doctors commonly use a blood test called the prostate-specific antigen, or PSA, test to look for early signs of the disease. A massive new review of clinical trials has updated our understanding of how well this test works. The findings suggest that relying on the PSA test alone likely reduces the number of men who die specifically from prostate cancer, and it might even reduce overall death rates compared to not screening at all.

Routine screening naturally leads to a spike in prostate cancer diagnoses, particularly cases that are localized, meaning the cancer has not spread beyond the prostate gland. However, catching these early cases appears to have a protective effect later on. The data shows routine screening could potentially reduce the number of aggressive, metastatic cancers that eventually spread to other parts of the body.

The researchers also looked at a newer screening approach that combines the traditional PSA blood test with a special protein panel, called a kallikrein test, and an MRI scan. So far, early evidence suggests this advanced combination has little to no impact on the number of cancer diagnoses compared to no screening, though it is still too soon to know exactly how it affects long-term survival rates.

Why it matters.

For patients and doctors, these findings help clarify a deeply confusing medical decision. While avoiding a fatal cancer is the ultimate goal of any screening program, this research highlights important cautions. The scientists noted that their confidence in the exact numbers is somewhat lowered by inconsistencies and limitations in the original studies.

More importantly, the medical community still does not have a complete picture of the potential harms. Diagnosing early prostate cancer can sometimes lead to unnecessary biopsies and aggressive treatments, which carry their own significant complications. Because we still lack sufficient data on these treatment-related side effects, patients should talk openly with their doctors. The decision to get a PSA test remains a personal balance between a likely reduction in cancer deaths and the risk of potential overtreatment.

From the source

The story in numbers.

Total randomised participants across 6 RCTs
789,086
Rate ratio for prostate cancer-specific mortality (PSA vs no screening)
0.87
Rate ratio for increased prostate cancer diagnoses (PSA vs no screening)
1.30
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Diagnostics

Simple AI Uses DNA to Accurately Classify Dozens of Cancers

Machine learning is often hyped in modern medicine, but highly complex algorithms that look flawless in the lab frequently fail in the real world. To solve this, scientists have developed a new artificial intelligence framework that takes a simpler, more reliable approach to diagnosing cancer. By analyzing DNA methylation, which are chemical tags that attach to DNA and influence how genes behave, researchers created a tool capable of classifying dozens of different cancers and healthy tissues with impressive precision. The research team trained their system using a massive dataset of over 10,000 tissue samples. Surprisingly, they found that a straightforward algorithm called logistic regression actually outperformed highly complex deep neural networks. By looking at 1,208 specific chemical markers on the DNA, their simple model achieved a 90 percent accuracy rate in distinguishing between 54 different healthy and cancerous tissue types. When tested on central nervous system tumors, the tool successfully identified 59 different subtypes with an outstanding 94 percent accuracy. To ensure these results were reliable, the team put their methodology to the test using an independent dataset of over 2,300 samples gathered from 28 different studies. They also introduced a special filtering technique to catch and remove abnormal biological data, which further boosted the model's overall performance and helped prevent artificially inflated success rates.

PubMed2 min read
Diagnostics

Current Methods for Diagnosing Brain Trauma in Athletes Fall Short

For years, the medical community has sought ways to identify chronic traumatic encephalopathy, a degenerative brain disease linked to repeated head impacts, in living patients. Doctors currently look for a specific group of symptoms known as traumatic encephalopathy syndrome to estimate if an athlete has underlying brain damage. However, new research suggests this evaluation method is highly unreliable. A recent study published in Nature Medicine reveals that the proposed clinical features used to diagnose this syndrome are poor predictors of actual brain pathology. Simply put, the behavioral and cognitive symptoms doctors look for do not accurately match the physical signs of the disease in the brain. Because these clinical features have such a low predictive value, researchers warn that relying on them carries a significant risk of misdiagnosis. It is worth noting that the initial abstract does not share specific sample sizes, statistical parameters, or patient demographics, making it difficult to quantify exactly how often these errors occur. Still, the core finding points to a major flaw in how doctors currently evaluate former athletes for brain trauma.

Nature Medicine1 min read
Diagnostics

Routine PET Scans Can Predict Lung Cancer Immunotherapy Success

Lung cancer patients often receive immunotherapy before surgery to help shrink their tumors, a process called neoadjuvant treatment. For doctors, a key challenge is figuring out if this early treatment is actually working to achieve a major pathologic response, which means most of the cancer cells have been successfully destroyed. In a recent study, researchers discovered that comparing routine imaging tests, known as PET-CT scans, can highly accurately predict this success. The research followed 90 patients with non-small cell lung cancer. The scientists found that looking at a single PET-CT scan taken before treatment could not predict how well a patient would fare. However, by calculating the percentage change in the tumor's metabolic activity before and after the immunotherapy, doctors could clearly spot the patients who were responding well. The single best indicator was a measurement tracking the peak energy use of the tumor, known as the maximum standardized uptake value. When this specific metabolic measurement dropped significantly, it proved to be an incredibly accurate sign that the cancer was retreating. Notably, tracking these changes on standard PET-CT scans was much more effective than relying on common molecular laboratory tests. The imaging approach significantly outperformed both PD-L1 expression and Tumor Mutational Burden, which are protein and genetic markers traditionally used to guide modern cancer care.

PubMed2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗
Routine PSA Tests Likely Save Lives, Updated Study Finds — Daily Strand